NKTR
Nektar Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.28 / 10
Outperform
Fund flow evaluation shows 7.94/10, reflecting robust money inflow despite short-term negative trends in most categories. Analyst perspective is overwhelmingly bullish with a Strong Buy rating from BTIG, but the limited analyst coverage (only one) tempers conviction.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-29
InstitutionBTIG
Times predicted3
Historical Win Rate66.7%
Is money flowing into or out of NKTR?
- NKTR holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.28/10 (Outperform).
